238 related articles for article (PubMed ID: 20606434)
1. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.
Baumann TP; Duyar H; Sollberger M; Kuhle J; Regeniter A; Gomez-Mancilla B; Schmidtke K; Monsch AU
Dement Geriatr Cogn Disord; 2010; 29(6):530-3. PubMed ID: 20606434
[TBL] [Abstract][Full Text] [Related]
2. Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio.
Beaufils E; Dufour-Rainfray D; Hommet C; Brault F; Cottier JP; Ribeiro MJ; Mondon K; Guilloteau D
J Alzheimers Dis; 2013; 33(3):775-80. PubMed ID: 22986776
[TBL] [Abstract][Full Text] [Related]
3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
4. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease?
Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L
Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
[TBL] [Abstract][Full Text] [Related]
9. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
[TBL] [Abstract][Full Text] [Related]
11. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
[TBL] [Abstract][Full Text] [Related]
12. CSF biomarkers in posterior cortical atrophy.
Seguin J; Formaglio M; Perret-Liaudet A; Quadrio I; Tholance Y; Rouaud O; Thomas-Anterion C; Croisile B; Mollion H; Moreaud O; Salzmann M; Dorey A; Bataillard M; Coste MH; Vighetto A; Krolak-Salmon P
Neurology; 2011 May; 76(21):1782-8. PubMed ID: 21525425
[TBL] [Abstract][Full Text] [Related]
13. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
[TBL] [Abstract][Full Text] [Related]
15. [A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].
Molinuevo JL; Gispert JD; Pujol J; Rojas S; Lladó A; Balasa M; Antonell A; Sánchez-Valle R; Rami L
Rev Neurol; 2012 May; 54(9):513-22. PubMed ID: 22532214
[TBL] [Abstract][Full Text] [Related]
16. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
18. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
